The Grinder Lab, New Brand & New Product for Coffee Enthusiasts
The Grinder Lab is proud to announce the launch of the TGL-747, a manual coffee grinder that stands apart for its precision, luxury, and innovation. Designed for coffee enthusiasts, this Swiss-made tool is set to upgrade how coffee is ground and enjoyed.
This press release features multimedia. View the full release here:
Exceptional Features and Benefits
The TGL-747 boasts a range of advanced features that make it the ultimate coffee-grinding solution:
Precision Grinding: With a 10 microns/click of vertical adjustment of the burrs and 50 clicks per revolution, the TGL-747 delivers the highest resolution on the market, making it espresso-capable and perfect for any brew method.
Superior Materials: Crafted from 316L surgical-grade stainless steel, this high-precision mechanical construction is supported by four ball bearings, ensuring durability and consistent performance.
Elegant Design: The stepless, easy-to-read, touch-sensitive, watch-inspired dial enhances usability, making it comfortable for all users, including those with visual impairments.
Stability and Safety: The TGL-747 features a stable, wide-base receiver, which provides exceptional stability. It prevents tilting or falling off the table, which could lead to damage.
Optimized for Comfort: Its thoughtful design prioritizes haptics and portability, allowing for a pleasant grinding experience while being lightweight enough for travel.
A Commitment to Excellence
Precision Matters™ to us, and we are here to deliver it. The TGL-747 is not just a coffee grinder, but a high-end precision tool designed for those who appreciate the art of coffee making. Its enhanced features offer an exceptional experience and optimal flavor in the cup.
Availability
The TGL-747 is available now through our website, www.TheGrinderLab.com, and select retailers.
After purchasing the grinder, we encourage you to use your serial number to join the TGL Club, a community hub featuring exclusive benefits and events.
Events
Join us at the Specialty Coffee Expo in Houston, Texas, from April 25-27, 2025, for a hands-on experience with the TGL-747 in action. Come to booth 1662 to feel, test, and explore its cutting-edge features live.
We will also be showcasing at World of Coffee Geneva 2025 in Geneva, Switzerland, from June 25-28, 2025, another great opportunity to connect and experience innovation firsthand. Meet us in booth 2528!
For More Information
For additional details, high-resolution images, or to schedule an interview, please contact:
Dr. Michel Nedeff – [email protected] Tel: +1 (786) 602-2263
The Grinder Lab – Precision Matters ™
SOURCE: The Grinder Lab
Copyright Business Wire 2025.
PUB: 03/17/2025 08:28 AM/DISC: 03/17/2025 08:28 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
2 hours ago
- New York Post
Ram boss sorry for ‘woke' pivot that killed gas-guzzling engine, brings back growling classic after backlash: ‘We got it wrong'
Ram admitted it screwed up by killing a legacy American-made engine known for its raw power — and is revved up to bring it back after facing major backlash. The automaker had discontinued the beloved HEMI V-8 engine from its 2025 Ram trucks as part of a 'woke' pivot by the since-ousted CEO of parent company Stellantis Carlos Tavares, But new Ram CEO Tim Kuniskis, who came out of retirement last last year, offered up a mea culpa over the decision to pull the plug on the engine that powered the top-selling truck for decades. 7 Ram Trucks CEO Tim Kuniskis appears in a new ad for the company in which he apologizes for ditching a beloved gas-powered engine. Youtube/Ram Trucks In a newly-released ad, Kuniskis publicly acknowledged the misstep and said Ram is reversing course by bringing back the gas-guzzling HEMI engine in 2026 models. 'We own it. We got it wrong. And we're fixing it,' Kuniskis announces in the commercial. Ram ditched the HEMI as part of its broader push toward meeting stricter emissions regulations enacted by the Biden administration as well as its goal of improving fuel efficiency across its lineup. President Trump administration has pushed to scrap many of Biden's green initiatives. 'When Ram made the decision to discontinue production of the iconic HEMI V-8, the internet erupted, and lifelong loyalists voiced their outrage across social media,' Lindsay Fifelski, head of Ram brand advertising, told Fast Company. 7 Kuniskis is seen in the ad getting behind the wheel of a Ram Truck as it speeds down a NASCAR runway. Youtube/Ram Trucks 'We knew we couldn't market our way around this moment; we had to meet it head-on.' The Ram ad also features screeching tires and Kuniskis narrating over the roar of engines as drives the Ram Truck on a NASCAR track. 'You hear that? That's our HEMI, and it's saying, 'I'm back,'' he bellows, as the truck blazes down the track. A fan chimes in: 'Did he say what I think he said? That thing's got a HEMI!' 'Hell, yeah, it does!' another said. 7 The ad features screeching tires and Kuniskis narrating over the roar of engines as he is drifting, doing doughnuts and taking hot laps on a NASCAR track. Youtube/Ram Trucks Later, amid tire smoke and cheering crowds, Kuniskis leaned into the hype. 'You want more? Buckle up. Ram's coming back to NASCAR,' he said. He offered up one last rallying cry — 'Let's f–king go!' — then ended the commercial with a promise: 'We're back in America's motorsport. The HEMI's back. And we ain't going anywhere.' 7 'You hear that? That's our HEMI, and it's saying, 'I'm back,'' he said, as the truck blazes down the track. Youtube/Ram Trucks Ram and its parent brand Dodge left NASCAR after the 2012 season. The commercial, created by ad agency Argonaut, doubles as an apology and a reintroduction of the HEMI, which is named for the hemispherical shape of the engine's combustion chambers. The HEMI is unique in that the shape of its chambers allows for better airflow, higher efficiency and greater power output. The engine delivers up to 717+ horsepower in supercharged variants and is prized for its durability, low-end torque and distinctive rumble. 7 The HEMI is unique in that the shape of its chambers allows for better airflow, higher efficiency and greater power output. Frisco Dodge The iconic engine was replaced by the new Hurricane lineup of more powerful and efficient 3.0-liter twin-turbo inline-six engines during the refresh of the fifth-generation Ram 1500 light-duty truck. The move aligned with parent company Stellantis' global electrification and downsizing strategy, which emphasized smaller, more efficient powertrains like the Hurricane. The company positioned the Hurricane as more powerful and fuel-efficient than the outgoing V8 — but the decision sparked backlash from loyalists who valued the HEMI's iconic rumble, durability, and cultural significance. 7 The engine delivers up to 717+ horsepower in supercharged variants. RAM Ram's overall sales dropped more than 18% year over year in 2024. Kuniskis told CNBC that he expects the HEMI to account for 25% to 40% of Ram 1500 pickup truck sales in 2025. The renewed interest suggests the company's about-face could deliver not just goodwill, but a needed boost at the dealership level. 7 Ram Trucks and its parent company Stellantis are joining other automakers in moving away from full electrification of their fleets. Youtube/Ram Trucks Stellantis, the fourth largest automaker in the world — whose portfolio of brands includes Ram, Dodge, Fiat, Chrysler, Peugeot and Jeep — is just the latest automaker to scale back the push toward electrifying its fleet of cars and trucks. Several major car companies — including Ford, GM and Mercedes-Benz — have scaled back or delayed their electrification plans due to weaker-than-expected consumer demand, high production costs and charging infrastructure concerns. Ford is pivoting toward hybrids and GM postponed several EV launches. By late 2023, electric vehicle inventory was piling up on dealership lots, with EVs taking more than three times longer to sell than gas-powered cars, signaling a sharp slowdown in consumer demand.
Business Wire
3 hours ago
- Business Wire
Hamilton ETFs Launches USD Version of HAMILTON CHAMPIONS™ U.S. Dividend Index ETF
TORONTO--(BUSINESS WIRE)--Hamilton Capital Partners Inc. (" Hamilton ETFs") is pleased to announce the launch of a US$ Unhedged Unit class of the HAMILTON CHAMPIONS™ U.S. Dividend Index ETF (' SMVP '). SMVP has closed the offering of its US$ Unhedged Units. Such Units will begin trading on Monday, June 16, 2025, on the Toronto Stock Exchange (' TSX '), under the ticker symbol 'SMVP.U'. 'When we launched the HAMILTON CHAMPIONS™ U.S. Dividend Index ETF (SMVP), our goal was to provide investors with a high-quality, blue-chip portfolio of U.S. dividend growth leaders—at a low cost. Today, we are pleased to expand the offering with the launch of SMVP.U, a US$ Unhedged Unit, giving investors greater choice and flexibility in how they access this strategy. By offering both CAD-hedged and USD unhedged options, we're responding to investor demand and helping more Canadians tailor their portfolios to suit their currency preferences and investment objectives,' said Pat Sommerville, Senior Partner, Co-President at Hamilton ETFs. For more information on SMVP and the rest of Hamilton ETFs' innovative suite of ETFs, please visit About Hamilton Capital Partners Inc. (Hamilton ETFs) With over $8 billion in assets under management, Hamilton ETFs is one of Canada's fastest-growing ETF providers, offering a suite of innovative exchange traded funds (ETFs) designed to maximize income and growth from trusted sectors in Canada and across the globe. The firm is also an active commentator on the global financial services sector and Canadian banks; the firm's most recent Insights can be found at Commissions, management fees and expenses all may be associated with an investment in exchange traded funds (ETFs). Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Certain statements contained in this news release constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to a future outlook and anticipated distributions, events or results and may include statements regarding future financial performance. In some cases, forward-looking information can be identified by terms such as "may", "will", "should", "expect", "anticipate", "believe", "intend" or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Hamilton ETFs undertakes no obligation to update publicly or otherwise revise any forward-looking statement whether as a result of new information, future events or other such factors which affect this information, except as required by law.
